REFERENCES

1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413–46. 

2. Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. The Lancet Neurology. 2020;19(1):81–92. 

3. Liao Z, Bu Y, Li M, Han R, Zhang N, Hao J, et al. Remote ischemic conditioning improves cognition in patients with subcortical ischemic vascular dementia. BMC neurology. 2019;19:1–8. 

4. Gustavsson AM, Van Westen D, Stomrud E, Engström G, Nägga K, Hansson O. Midlife atherosclerosis and development of Alzheimer or vascular dementia. Annals of neurology. 2020;87(1):52–62. 

5. Deardorff WJ, Grossberg GT. Behavioral and psychological symptoms in Alzheimer’s dementia and vascular dementia. Handbook of clinical neurology. 2019;165:5–32. 

6. Choi S, Kim K, Chang J, Kim SM, Kim SJ, Cho HJ, et al. Association of chronic periodontitis on Alzheimer’s disease or vascular dementia. Journal of the American Geriatrics Society. 2019;67(6):1234–9. 

7. Iwagami M, Qizilbash N, Gregson J, Douglas I, Johnson M, Pearce N, et al. Blood cholesterol and risk of dementia in more than 1· 8 million people over two decades: a retrospective cohort study. The Lancet Healthy Longevity. 2021;2(8):e498–506. 

8. Inoue Y, Shue F, Bu G, Kanekiyo T. Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease. Molecular Neurodegeneration. 2023;18(1):1–22. 

9. Asby D, Boche D, Allan S, Love S, Miners JS. Systemic infection exacerbates cerebrovascular dysfunction in Alzheimer’s disease. Brain. 2021;144(6):1869–83. 

10. Tayler H, Miners JS, Güzel Ö, MacLachlan R, Love S. Mediators of cerebral hypoperfusion and blood-brain barrier leakiness in Alzheimer’s disease, vascular dementia and mixed dementia. Brain Pathology. 2021;31(4):e12935. 

11. Takeda S, Rakugi H, Morishita R. Roles of vascular risk factors in the pathogenesis of dementia. Hypertension Research. 2020;43(3):162–7. 

12. Apátiga-Pérez R, Soto-Rojas LO, Campa-Córdoba BB, Luna-Viramontes NI, Cuevas E, Villanueva-Fierro I, et al. Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metabolic brain disease. 2022;37(1):39–50. 

13. D’Arrigo JS. Nanotherapy for Alzheimer’s disease and vascular dementia: Targeting senile endothelium. Advances in Colloid and Interface Science. 2018;251:44–54. 

14. Sharma C, Woo H, Kim SR. Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease. Biomedicines. 2022;10(4):742. 

15. Schroer MA, Hu PS, Tomasovicova N, Batkova M, Zakutanska K, Wu PY, et al. Dependence of the Nanoscale Composite Morphology of Fe3O4 Nanoparticle-Infused Lysozyme Amyloid Fibrils on Timing of Infusion: A Combined SAXS and AFM Study. Molecules. 2021;26(16):4864. 

16. Javed I, He J, Kakinen A, Faridi A, Yang W, Davis TP, et al. Probing the aggregation and immune response of human islet amyloid polypeptides with ligand-stabilized gold nanoparticles. ACS applied materials & interfaces. 2019;11(11):10462–71. 

17. Jo I, Kang JW, Kim KS. Synthesis of cadmium telluride nanoparticles using thioglycolic acid, thioglycerol, and L-cysteine. Journal of Nanoscience and Nanotechnology. 2021;21(7):4073–6. 

18. Nithin BR, Bhuyar P, Maniam GP, Rahim MHA, Govindan N. Environment Friendly Approach for Plant Mediated Green Biosynthesis of Gold Nanoparticles and Their Modern Applications in Biomedical Aspects—an Updated Report. BioNanoScience. 2023;1–24. 

19. Asadinezhad M, Azimian H, Ghadiri H, Khademi S. Gold nanoparticle parameters play an essential role as CT imaging contrast agents. Journal of Nanostructures. 2021;11(4):668–77. 

20. TYAl-Abdullah Z, AL-SHAWI AA, Aboud MN, Al Abdul Aziz B, QM Al-Furaiji H, Luaibi IN. Synthesis and Analytical Characterization of Gold Nanoparticles using Microwave-Assisted Extraction System and Study their Application in Degradation. Journal of Nanostructures. 2020;10(4):682–90. 

21. Eze FN, Eze RC, Ovatlarnporn C. Insights into the remarkable attenuation of hen egg white lysozyme amyloid fibril formation mediated by biogenic gold nanoparticles stabilized by quercetin-functionalized tara gum. International Journal of Biological Macromolecules. 2023;232:123044. 

22. Asil SM, Ahlawat J, Barroso GG, Narayan M. Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases. Biomaterials science. 2020;8(15):4109–28. 

23. Serafín V, Razzino CA, Gamella M, Pedrero M, Povedano E, Montero-Calle A, et al. Disposable immunoplatforms for the simultaneous determination of biomarkers for neurodegenerative disorders using poly (amidoamine) dendrimer/gold nanoparticle nanocomposite. Analytical and Bioanalytical Chemistry. 2021;413:799–811. 

24. Li-Na MA, Dian-Jun LIU, Zhen-Xin W. Synthesis and applications of gold nanoparticle probes. Chinese Journal of Analytical Chemistry. 2010;38(1):1–7. 

25. Karmakar S, Sarkar N, Pandey LM. Proline functionalized gold nanoparticles modulates lysozyme fibrillation. Colloids and Surfaces B: Biointerfaces. 2019;174:401–8. 

26. Sizova DV, Raiker S, Lakheram D, Rao V, Proffitt A, Jmeian Y, et al. Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis. Biochemistry and Biophysics Reports. 2023;34:101442. 

27. Lyubchenko Y. Amyloid cascade hypothesis for Alzheimer’s disease. Does it work under physiological conditions? Precision Nanomedicine. 2023;1013–22. 

28. Jamuna NA, Kamalakshan A, Dandekar BR, Chittilappilly Devassy AM, Mondal J, Mandal S. Mechanistic Insight into the Amyloid Fibrillation Inhibition of Hen Egg White Lysozyme by Three Different Bile Acids. The Journal of Physical Chemistry B. 2023;127(10):2198–213. 

29. Khan AN, Nabi F, Khan RH. Mechanistic and biophysical insight into the inhibitory and disaggregase role of antibiotic moxifloxacin on human lysozyme amyloid formation. Biophysical Chemistry. 2023;298:107029. 

30. Anker S, Hinderhofer K, Baur J, Haupt C, Röcken C, Beimler J, et al. Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant. Amyloid. 2022;29(4):245–54. 

31. Debnath K, Sarkar AK, Jana NR, Jana NR. Inhibiting protein aggregation by small molecule-based colloidal nanoparticles. Accounts of Materials Research. 2021;3(1):54–66. 

32. Geng H, Pan Y chen, Zhang R, Gao D, Wang Z, Li B, et al. Binding to amyloid-β protein by photothermal blood-brain barrier-penetrating nanoparticles for inhibition and disaggregation of fibrillation. Advanced Functional Materials. 2021;31(41):2102953.